Biggest News Aggregation in the World
📰 Targeting Module News

Targeting Module News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Targeting Module. Real-time updates on events, politics, business and more.

GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd EHA-EBMT European CAR T-Cell Meeting

Share this article DRESDEN, Germany, Feb. 3, 2021 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced interim data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the Virtual 3 rd EHA-EBMT European CAR-T-Cell Meeting, which is held from February 04-06, 2021. The data are being presented as oral presentation by Dr. Ma...
Prnewswire Gemoa Martin Wermke Sabrina Kraus Jana Fiebiger Michael Pehl Bristol Myers Squibb

GEMoaB Announces Clinical Data Presentations on Their Lead Asset UniCAR-T-CD123 in relapsed/refractory AML at the Upcoming EHA-EBMT 3rd European CAR T-Cell Meeting

Share this article DRESDEN, Germany, Jan. 7, 2021 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to- treat cancers, today announced the acceptance of two presentations on clinical data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the 2021 EHA-EBMT 3rd European CAR T-Cell Meeting, being held from February 4-6.  So far, CAR-T cell therapy in ...
Prnewswire Gemoa Martin Wermke Sabrina Kraus Jana Fiebiger Michael Pehl Bristol Myers Squibb

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science